theMednetRegister
  • Community
    • Overview
    • Experts
    • Editors
    • Fellows
    • Code of conduct
    • AI Guidelines for Physicians
  • Company
    • About Us
    • FAQs
    • Privacy Policy
    • Terms of Use
    • Careers
    • Programs
  • News
    • News Releases
    • Press Coverage
    • Publications
    • Blog
  • Contact Us
  • Sign in

Rheumatology

csDMARDs   

Questions discussed in this category


Should MTX be avoided in RA patients with asymptomatic lung nodules?
If so, what would be an ideal DMARD in this setting?
1 Answer available

How long do you wait for response to corticosteroids and conventional synthetic DMARDs before considering IVIG in patients with HMGCR antibody positive IMNM?
1 Answer available

How does the presence of nonalcoholic fatty liver disease (NAFLD) impact your choice of csDMARD for RA?
1 Answer available

Should patients be screened for hepatitis B/C prior to starting a conventional synthetic DMARD such as methotrexate?
1 Answer available
8805846782757600


Papers discussed in this category


Semin. Arthritis Rheum., 2020 Mar 19
RISE registry reveals potential gaps in medication safety for new users of biologics and targeted synthetic DMARDs.

Related Topics in Rheumatology

  • Lung Cancer
  • Breast Cancer
  • Head and Neck Cancers
  • Hematologic Malignancies
  • Radiation Oncology
  • Gynecologic Oncology
  • Palliation
  • Neuro-Oncology
  • Gastrointestinal Cancers
  • Genitourinary Cancers

Copyright © 2025 theMednet
All Rights Reserved.